secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0000950170-23-028611
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Therapeutics stockholders approve doubling of authorized shares to 240M
--------------------------------------------------------------------------------

- Stockholders approved amendment to increase authorized common shares from 120M to 240M.
- Three Class I directors elected: Muna Bhanji, John F. Crowley, Jesse Goodman.
- Deloitte & Touche ratified as independent auditor for fiscal year 2023.
- Advisory say-on-pay vote approved with 65.8M for, 1.2M against.
- Amendment filed with Delaware Secretary of State on June 14, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023028611/0000950170-23-028611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023028611/ntla-20230614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-028611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer